Primary cutaneous T-cell lymphoma expressing FOXP3: A case report supporting the existence of malignancies of regulatory T cells

Journal of the American Academy of Dermatology

Volumn 61, Issue 2, 2009, Pages 348-355

  Marzano, Angelo V ^a   Vezzoli, Pamela ^a   Fanoni, Daniele ^a   Venegoni, Luigia ^a   Berti, Emilio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; ETRETIN; METHOTREXATE; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TRANSCRIPTION FACTOR FOXP3;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISEASE; MALE; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN MANIFESTATION; T CELL LEUKEMIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; ULTRAVIOLET B RADIATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CD4-POSITIVE T-LYMPHOCYTES; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL, CUTANEOUS; MALE; RISK ASSESSMENT; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 67650473615     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.11.894     Document Type: Article

References (30)

1. Willemze R., Jaffe E., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3783
2. Berger C.L., Heald P., Girardi M., and Edelson R.L. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. G Ital Dermatol Venereol 143 (2008) 43-54
3. Kung P., Berger C., Estrabook A., and Edelson R. Monoclonal antibodies for clinical investigation of human T lymphocytes. Int J Dermatol 22 (1983) 67-74
4. Picker L., Michie S., Rott L., and Butcher E. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 136 (1990) 1053-1068
5. Von Herrah M.G., and Harrison L.C. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 3 (2003) 223-232
6. + T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol 32 (2002) 1282-1291
7. Sakaguchi S., and Wood K.J. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
8. Bennet C.L., Cristie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20-21
9. Bottaro M., Berti E., Biondi A., Migone N., and Crosti L. Heteroduplex analysis of T-cell receptor γ gene rearrangement for diagnosis and monitoring of cutaneous T-cell lymphomas. Blood 83 (1994) 3271-3278
10. Gallego S., Mangano A., Gastaldello R., Sen L., and Medeot S. Usefulness of a nested-polymerase chain reaction for molecular diagnosis of human T-cell lymphotrophic virus type I/II. Mem Inst Oswaldo Cruz 99 (2004) 377-380
11. McClain K.L., Leach C.T., Jenson H.B., Joshi V.V., Pollock B.M., Parmley R.T., et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 75 (1995) 87-94
12. Corbellino M., Pizzuto M., Bestetti G., Corsico L., Piazza M., Pigozzi B., et al. Absence of Kaposi's sarcoma-associated herpesvirus DNA sequences in multiple myeloma. Blood 93 (1999) 1110-1111
13. Chmielewicz B., Goltz M., and Ehlers B. Detection and multigenic characterization of a novel gammaherpesvirus in goats. Virus Res 75 (2001) 87-94
14. Yano H., Ishida T., Inagaki A., Ishii T., Kusumoto S., Komatsu H., et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 120 (2007) 2052-2057
15. Roncador G., Garcia J.F., Garcia J.F., Maestre L., Lucas E., Menarguez J., et al. FOXP3, a selective marker for a subset of adult T-cell leukemia/lymphoma. Leukemia 19 (2005) 2247-2253
16. Karube K., Ohshima K., Tsuchiya T., Yamaguchi T., Kawano R., Suzumiya J., et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukemia/lymphoma cells. Br J Haematol 126 (2004) 81-84
17. Hallermann V., Niermann C., and Schulze H.J. Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides. Eur J Haematol 78 (2007) 260-263
18. Berger C.L., Tigelaar R., Cohen J., Mariwalla K., Trinh J., Wang N., et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105 (2005) 1640-1647
19. Axelrod P.I., Lorber B., and Vonderheid E.C. Infections complicating mycosis fungoides and Sézary syndrome. JAMA 267 (1992) 1354-1358
20. + T cells with regulatory properties from human blood. J Exp Med 193 (2001) 1303-1310
21. Assadullah K., Docke W.D., Haeussler A., Sterry W., and Volk H.D. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107 (1996) 833-837
22. Bagot M., Nikolova M., Schrim-Chabanette F., Wechsier J., Boumsell L., and Benussan A. Crosstalk between tumor lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann N Y Acad Sci 941 (2001) 31-38
23. + regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21 (2007) 2512-2518
24. Gjerdrum L.M., Woetmann A., Odum N., Hother C., Henrik-Nielsen R., Gniadecki R., et al. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. Eur J Haematol 80 (2008) 483-489
25. + cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 20 (2006) 1123-1129
26. + T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 126 (2006) 2217-2223
27. Wong H.K., Wilson A.J., Gibson H.M., Hafner M.S., Hedgcock C.J., Berger C.L., et al. Increased expression of CTLA-4 in malignant T cells from patients with mycosis fungoides-cutaneous T-cell lymphoma. J Invest Dermatol 126 (2006) 212-219
28. Henney J.E. From the Food and Drug Administration. JAMA 283 (2000) 1131
29. Zhang C., Hazarika P., Ni X., Weidner D.A., and Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8 (2002) 1234-1240
30. Youn H.K., Duvic M., Obitz E., Gniadecki R., Iversen L., Osterborg A., et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109 (2007) 4655-4662